Age, Biography and Wiki

Martin Rogers was born on 1981. Discover Martin Rogers's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 39 years old?

Popular As N/A
Occupation N/A
Age 40 years old
Zodiac Sign N/A
Born
Birthday
Birthplace N/A
Nationality

We recommend you to check the complete list of Famous People born on . He is a member of famous with the age 40 years old group.

Martin Rogers Height, Weight & Measurements

At 40 years old, Martin Rogers height not available right now. We will update Martin Rogers's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Martin Rogers Net Worth

His net worth has been growing significantly in 2020-2021. So, how much is Martin Rogers worth at the age of 40 years old? Martin Rogers’s income source is mostly from being a successful . He is from . We have estimated Martin Rogers's net worth, money, salary, income, and assets.

Net Worth in 2021 $1 Million - $5 Million
Salary in 2020 Under Review
Net Worth in 2019 Pending
Salary in 2019 Under Review
House Not Available
Cars Not Available
Source of Income

Martin Rogers Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia Martin Rogers Wikipedia
Imdb

Timeline

2012

* Became a Nasdaq-listed company. Prima's ADRs started trading on Nasdaq in April 2012.

Prima announced in May 2012 that Rogers would be stepping down as CEO. He left Prima at the end of August 2012. By the end of tenure Prima had made it into the S&P/ASX 300.

Since 2012 Rogers has been involved at board level in a number of ASX-listed biotech companies, including Cellmid (ASX: CDY) between September 2012 and June 2015; Rhinomed (ASX: RNO), since September 2012; OncoSil Medical (ASX: OSL) since April 2013; and Actinogen (ASX: ACW), since September 2014.

2010

* Moved CVac into mid-stage clinical studies. The extra funding Prima was able to raise allowed CVac to be taken into Phase IIb studies from 2010 with a runway into Phase III.

2007

Rogers was part of an investor group that effectively took control of Prima BioMed in late 2007, when he was appointed a director. At that time Prima had Phase IIa data for its CVac cancer vaccine product, but did not have the funds to progress further. Under Rogers' leadership Prima achieved four main things:

* Raised approx. A$82m in new capital. Rogers started with a 1-for-2 rights issue in October 2007 (A$2.0m) and followed with Share Purchase Plans in December 2008 and June 2009 (each approx A$0.2m) and a share placement in June 2009 (A$1.5m) before securing an equity funding line which allowed A$14.7m to be raised between July 2011 and March 2011. From late 2009 capital raising became easier. A third Share Purchase Plan in December 2009 raised A$13.7m while a placement and associated Share Purchase Plan in June 2011 raised A$41.4m. Between 2009 and 2012 the exercise of options brought in another A$8.4m (A$1.3m in 2009/10, A$5.1m in 2010/11 and A$2.0m in 2011/12).

* Experienced an increase in its share price. Prima stock re-rated 19-fold between December 2007 and April 2011, creating a company with a market value of ~A$300m.

1999

Rogers attended the University of New South Wales between 1999 and 2004 where he gained a double degree in chemical engineering and computer science. Between 2004 and 2007 he engaged in a number of entrepreneurial pursuits as well as worked at Macquarie Bank.

1981

Martin Rogers (born 1981) is an Australian bioentrepreneur who has been associated since 2007 with a number of ASX-listed biotechnology companies, including Prima BioMed, which he led from 2007 to 2012.